Valuation: argenx SE

Capitalization 43.02B 51.05B 39.26B 37.48B 69.6B 4,625B 71.98B 456B 181B 2,228B 191B 188B 7,783B P/E ratio 2025 *
47.4x
P/E ratio 2026 * 28.7x
Enterprise value 40.12B 47.61B 36.61B 34.95B 64.9B 4,313B 67.11B 425B 169B 2,078B 179B 175B 7,257B EV / Sales 2025 *
11.2x
EV / Sales 2026 * 7.67x
Free-Float
99.23%
Yield 2025 *
0.02%
Yield 2026 * 0.04%
1 day+0.31%
1 week-1.82%
Current month-0.11%
1 month+4.64%
3 months-9.64%
6 months+27.26%
Current year-1.93%
1 week 683.8
Extreme 683.8
713.2
1 month 663.2
Extreme 663.2
737
Current year 660.4
Extreme 660.4
737
1 year 456.6
Extreme 456.6
810
3 years 271
Extreme 271
810
5 years 201.4
Extreme 201.4
810
10 years 9.23
Extreme 9.23
810
Manager TitleAgeSince
Chief Executive Officer 54 2008-07-14
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Director/Board Member 54 2014-06-30
Chairman 68 2008-10-14
Director/Board Member 76 2015-05-12
Change 5d. change 1-year change 3-years change Capi.($)
+0.31%-1.82%+12.73%+101.78% 50.89B
+2.70%+8.02%+82.02%+16.85% 44.34B
-1.52%-3.22%+83.63%+645.01% 31.66B
-3.31%+0.21%-5.48%-25.26% 27.45B
-3.24%+6.21%+91.94%-38.00% 21.91B
-0.03%-5.36%+37.00%-30.28% 18.41B
-1.65%-1.61%+134.20% - 13.07B
+0.10%+2.87%+85.19%+132.47% 12.4B
-4.07%+5.63%-25.24%+529.25% 11.76B
-0.56%+0.78%+30.18%+143.30% 11.15B
Average -1.12%+2.18%+52.62%+163.90% 24.3B
Weighted average by Cap. -0.61%+1.89%+50.72%+146.65%

Financials

2025 *2026 *
Net sales 3.59B 4.26B 3.27B 3.12B 5.8B 386B 6B 38.02B 15.12B 186B 15.96B 15.63B 649B 5.03B 5.97B 4.59B 4.38B 8.14B 541B 8.42B 53.34B 21.21B 261B 22.39B 21.93B 910B
Net income 978M 1.16B 893M 852M 1.58B 105B 1.64B 10.37B 4.12B 50.65B 4.35B 4.26B 177B 1.76B 2.08B 1.6B 1.53B 2.84B 189B 2.94B 18.62B 7.41B 90.99B 7.82B 7.66B 318B
Net Debt -2.91B -3.45B -2.65B -2.53B -4.7B -312B -4.86B -30.81B -12.25B -151B -12.93B -12.67B -526B -4.45B -5.29B -4.07B -3.88B -7.21B -479B -7.45B -47.22B -18.78B -231B -19.82B -19.42B -806B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,599
Date Price Change Volume
26-02-12 703.00 +0.31% 66,283
26-02-11 700.80 -1.16% 50,149
26-02-10 709.00 +1.05% 55,291
26-02-09 701.60 +0.86% 56,798
26-02-06 695.60 -2.85% 88,325
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
703.00EUR
Average target price
815.51EUR
Spread / Average Target
+16.00%

Quarterly revenue - Rate of surprise